KR20220113543A - 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법 - Google Patents

미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20220113543A
KR20220113543A KR1020227026051A KR20227026051A KR20220113543A KR 20220113543 A KR20220113543 A KR 20220113543A KR 1020227026051 A KR1020227026051 A KR 1020227026051A KR 20227026051 A KR20227026051 A KR 20227026051A KR 20220113543 A KR20220113543 A KR 20220113543A
Authority
KR
South Korea
Prior art keywords
antigen
cell
cells
tumor
dendritic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227026051A
Other languages
English (en)
Korean (ko)
Inventor
알톤 엘. 보인톤
말닉스 엘. 보쉬
Original Assignee
노쓰웨스트 바이오써라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노쓰웨스트 바이오써라퓨틱스, 인크. filed Critical 노쓰웨스트 바이오써라퓨틱스, 인크.
Priority to KR1020237044465A priority Critical patent/KR20240005984A/ko
Publication of KR20220113543A publication Critical patent/KR20220113543A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020227026051A 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법 Ceased KR20220113543A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237044465A KR20240005984A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74888505P 2005-12-08 2005-12-08
US60/748,885 2005-12-08
PCT/US2006/047083 WO2007067782A2 (en) 2005-12-08 2006-12-08 Compositions and methods for inducing the activation of immature monocytic dendritic cells
KR1020217002605A KR20210013327A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217002605A Division KR20210013327A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237044465A Division KR20240005984A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20220113543A true KR20220113543A (ko) 2022-08-12

Family

ID=38123555

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020227026051A Ceased KR20220113543A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
KR1020187011878A Ceased KR20180049169A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
KR1020157017377A Ceased KR20150082688A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
KR1020217002605A Ceased KR20210013327A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
KR1020237044465A Ceased KR20240005984A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
KR1020087016423A Ceased KR20080109717A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한조성물 및 방법

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020187011878A Ceased KR20180049169A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
KR1020157017377A Ceased KR20150082688A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
KR1020217002605A Ceased KR20210013327A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
KR1020237044465A Ceased KR20240005984A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
KR1020087016423A Ceased KR20080109717A (ko) 2005-12-08 2006-12-08 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한조성물 및 방법

Country Status (14)

Country Link
US (2) US20080254537A1 (https=)
EP (3) EP3805367A1 (https=)
JP (7) JP5954918B2 (https=)
KR (6) KR20220113543A (https=)
CN (2) CN103589684A (https=)
AR (1) AR056851A1 (https=)
AU (1) AU2006321794A1 (https=)
BR (1) BRPI0619499A2 (https=)
CA (1) CA2632263C (https=)
CR (1) CR10048A (https=)
IL (2) IL191930A (https=)
RU (1) RU2008122550A (https=)
TW (1) TW200800252A (https=)
WO (1) WO2007067782A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002232560A1 (en) 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2758834C (en) * 2008-04-14 2017-11-07 Irx Therapeutics, Inc. Primary cell derived biologic modified manufacturing process
US8728806B2 (en) * 2008-12-06 2014-05-20 The Board Of Regents, The University Of Texas System Methods and compositions related to Th-1 dendritic cells
JP2012523379A (ja) * 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
WO2011011688A2 (en) * 2009-07-24 2011-01-27 Rhode Island Hospital DENDRITIC CELL VACCINES FOR ASPARAGINYL- β - HYDROXYLASE EXPRESSING TUMORS
CN102725634B (zh) * 2009-08-24 2016-01-20 纽约哥伦比亚大学理事会 用于测定cd8+t细胞的健康的测试法
CA2777400C (en) 2009-10-12 2018-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysin in immunotherapy
ES2667476T3 (es) 2009-12-08 2018-05-11 Irx Therapeutics, Inc. Método para invertir la supresión inmunitaria de células de Langerhans
US9476029B2 (en) * 2010-11-13 2016-10-25 Lung-Ji Chang Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells
NL2009102C2 (en) * 2012-07-02 2014-01-06 Dcprime B V Method for dc-loading.
TWI503414B (zh) * 2012-07-05 2015-10-11 Fullhope Biomedical Co Ltd 一種製備專一性ｔ細胞之配方、方法及其配方製備方法
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
CN104981258B (zh) 2012-12-12 2017-10-20 奥比思健康解决方案有限责任公司 用于组织再生的组合物、其制备方法及其用途
SI2788474T1 (sl) * 2012-12-18 2016-01-29 Immunicum Ab Ko-diferenciacija monocitov iz alogenskih darovalcev
CN104936612B (zh) * 2013-09-05 2021-01-01 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
CN103756960A (zh) * 2013-12-04 2014-04-30 深圳市合一康生物科技有限公司 一种高毒性、高增值能力的人d-cik细胞的专用试剂盒
CN103784950A (zh) * 2014-01-22 2014-05-14 北京弘润源生物技术有限公司 乳腺癌特异抗原表位多肽负载的树突状细胞疫苗制备及其试剂盒
US10166195B2 (en) 2014-03-05 2019-01-01 Orbis Health Solutions, Llc Vaccine delivery systems using yeast cell wall particles
CN103800897B (zh) * 2014-03-12 2017-03-22 李金珍 一种肿瘤特异抗原表位多肽负载的树突状细胞疫苗制备方法及其试剂盒
WO2015199402A1 (ko) * 2014-06-23 2015-12-30 제이더블유크레아젠 주식회사 특정 유전자 발현이 증가된 수지상세포의 제조방법 및 이를 이용하여 제조된 수지상세포를 포함하는 자가면역질환 치료 또는 예방용 조성물
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
RU2749610C2 (ru) * 2015-09-15 2021-06-16 Нортвест Байотерапьютикс, Инк. Способы, относящиеся к композициям активированных дендритных клеток и к иммунотерапевтическому лечению индивидуумов с прогрессирующим раком
CN105647867A (zh) * 2016-02-28 2016-06-08 深圳爱生再生医学科技有限公司 诱导树突状细胞成熟的方法和树突状细胞
CN105670994A (zh) * 2016-02-28 2016-06-15 深圳爱生再生医学科技有限公司 Dc诱导剂及其应用
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
JP6854290B2 (ja) * 2016-09-01 2021-04-07 株式会社理研免疫再生医学 ナチュラルキラーｔ（ｎｋｔ）細胞を刺激する樹状細胞の製造方法、ｎｋｔ細胞を刺激する樹状細胞、ｎｋｔ細胞を刺激する樹状細胞とｎｋｔ細胞とを含む細胞組成物の製造方法およびｎｋｔ細胞を刺激する樹状細胞とｎｋｔ細胞とを含む細胞組成物
JP2019528756A (ja) * 2016-09-29 2019-10-17 ハダシット メディカル リサーチ サービシズ アンド ディベロップメント リミテッド 樹状細胞調製物、その組成物及びその使用方法
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
JP6881333B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
JP6881332B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
JP6881331B2 (ja) * 2018-01-29 2021-06-02 株式会社三洋物産 遊技機
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
JP2021533759A (ja) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法
CN110106145B (zh) * 2019-06-12 2021-02-12 蓝莲(杭州)生物科技有限公司 一种未成熟树突状细胞培养液及其未成熟树突状细胞的制备方法
EP4151224B1 (en) * 2020-05-15 2025-12-31 Seoul National University R & DB Foundation COMPOSITION TO IMPROVE THE IMMUNE RESPONSE THROUGH THE USE OF AN ACTIVATION FUNCTION OF DENDRITIC CELLS FROM STROMAL VASCULAR FRACTIONS ISOLATED FROM ADIPOSE TISSUES
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
KR102818249B1 (ko) * 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US20010007659A1 (en) * 1997-04-17 2001-07-12 The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
AU2002326463A1 (en) 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
CA2459713C (en) * 2001-09-06 2015-08-18 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
CN1713951B (zh) 2002-06-19 2010-05-26 西北生物治疗药物公司 切向流过滤设备和白细胞富集方法
AT412145B (de) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
RU2364625C2 (ru) * 2003-02-27 2009-08-20 Норсуэст Байотерапьютикс, Инк. Генерирование дендритных клеток из моноцитарных предшественников дендритных клеток с помощью gm-csf в отсутствие дополнительных цитокинов

Also Published As

Publication number Publication date
KR20080109717A (ko) 2008-12-17
JP2023171524A (ja) 2023-12-01
CN103589684A (zh) 2014-02-19
JP5954918B2 (ja) 2016-07-20
JP2019062904A (ja) 2019-04-25
EP3072958A1 (en) 2016-09-28
JP2013223517A (ja) 2013-10-31
US20080254537A1 (en) 2008-10-16
WO2007067782A3 (en) 2008-02-14
US20120244620A1 (en) 2012-09-27
CA2632263A1 (en) 2007-06-14
JP2009518045A (ja) 2009-05-07
CR10048A (es) 2008-09-17
KR20210013327A (ko) 2021-02-03
EP3805367A1 (en) 2021-04-14
EP1957634A4 (en) 2010-01-27
AR056851A1 (es) 2007-10-24
AU2006321794A1 (en) 2007-06-14
KR20150082688A (ko) 2015-07-15
KR20240005984A (ko) 2024-01-12
JP2021045176A (ja) 2021-03-25
IL229348B (en) 2018-12-31
EP1957634A2 (en) 2008-08-20
BRPI0619499A2 (pt) 2011-10-04
KR20180049169A (ko) 2018-05-10
IL229348A0 (en) 2013-12-31
IL191930A (en) 2013-11-28
TW200800252A (en) 2008-01-01
JP2016105725A (ja) 2016-06-16
JP2017158595A (ja) 2017-09-14
WO2007067782A2 (en) 2007-06-14
RU2008122550A (ru) 2010-01-20
CA2632263C (en) 2022-01-11
CN101336291A (zh) 2008-12-31
IL191930A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
JP5954918B2 (ja) 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法
JP2009518045A5 (https=)
AU2010201319B2 (en) Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines
EP1806395A1 (en) Maturation of dendritic cells
CA2509058A1 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
KR20130103492A (ko) 수지상 세포를 제조하기 위한 조성물 및 방법
AU2013206016B2 (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
HK40051623A (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
AU2018260971B2 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
HK1193842A (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
HK1128161A (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
MX2008007289A (es) Composiciones y metodos para inducir la activacion de celulas dendriticas monociticas inmaduras
AU2013234394B2 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220727

Application number text: 1020217002605

Filing date: 20210126

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220826

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220922

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230725

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220922

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20231222

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20230725

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023101002791

Request date: 20231222

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20240122

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20240122

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2023101002791

Request date: 20231222

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20240122

WITB Written withdrawal of application